vs
dLocal Ltd（DLO）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
dLocal Ltd的季度营收约是Ultragenyx Pharmaceutical Inc.的1.6倍（$337.9M vs $207.3M），dLocal Ltd净利率更高（16.5% vs -62.0%，领先78.5%），dLocal Ltd同比增速更快（65.2% vs 25.9%），dLocal Ltd自由现金流更多（$99.8M vs $-100.8M）
dLocal是一家总部位于乌拉圭的金融科技企业，专注于提供跨境支付解决方案，搭建全球商户与新兴市场之间的支付链路，助力国际商户顺畅接入新兴市场本地支付网络，高效开展跨境业务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
DLO vs RARE — 直观对比
营收规模更大
DLO
是对方的1.6倍
$207.3M
营收增速更快
DLO
高出39.3%
25.9%
净利率更高
DLO
高出78.5%
-62.0%
自由现金流更多
DLO
多$200.6M
$-100.8M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $337.9M | $207.3M |
| 净利润 | $55.6M | $-128.6M |
| 毛利率 | 34.3% | — |
| 营业利润率 | 18.6% | -54.7% |
| 净利率 | 16.5% | -62.0% |
| 营收同比 | 65.2% | 25.9% |
| 净利润同比 | 87.3% | 3.5% |
| 每股收益（稀释后） | $0.18 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DLORARE
| Q4 25 | $337.9M | $207.3M | ||
| Q3 25 | $282.5M | $159.9M | ||
| Q2 25 | — | $166.5M | ||
| Q1 25 | — | $139.3M | ||
| Q4 24 | $204.5M | $164.6M | ||
| Q3 24 | $185.8M | $139.5M | ||
| Q2 24 | — | $147.0M | ||
| Q1 24 | — | $108.8M |
净利润DLORARE
| Q4 25 | $55.6M | $-128.6M | ||
| Q3 25 | $141.3M | $-180.4M | ||
| Q2 25 | — | $-115.0M | ||
| Q1 25 | — | $-151.1M | ||
| Q4 24 | $29.7M | $-133.2M | ||
| Q3 24 | $90.8M | $-133.5M | ||
| Q2 24 | — | $-131.6M | ||
| Q1 24 | — | $-170.7M |
毛利率DLORARE
| Q4 25 | 34.3% | — | ||
| Q3 25 | 36.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 40.9% | — | ||
| Q3 24 | 42.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率DLORARE
| Q4 25 | 18.6% | -54.7% | ||
| Q3 25 | 19.7% | -106.9% | ||
| Q2 25 | — | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | 20.7% | -74.3% | ||
| Q3 24 | 22.1% | -94.6% | ||
| Q2 24 | — | -79.1% | ||
| Q1 24 | — | -151.9% |
净利率DLORARE
| Q4 25 | 16.5% | -62.0% | ||
| Q3 25 | 50.0% | -112.8% | ||
| Q2 25 | — | -69.0% | ||
| Q1 25 | — | -108.5% | ||
| Q4 24 | 14.5% | -80.9% | ||
| Q3 24 | 48.9% | -95.7% | ||
| Q2 24 | — | -89.5% | ||
| Q1 24 | — | -156.8% |
每股收益（稀释后）DLORARE
| Q4 25 | $0.18 | $-1.28 | ||
| Q3 25 | $0.17 | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | $0.09 | $-1.34 | ||
| Q3 24 | $0.09 | $-1.40 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $719.9M | $421.0M |
| 总债务越低越好 | $86.7M | — |
| 股东权益账面价值 | $569.4M | $-80.0M |
| 总资产 | $1.5B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资DLORARE
| Q4 25 | $719.9M | $421.0M | ||
| Q3 25 | $604.5M | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | $425.2M | $174.0M | ||
| Q3 24 | $560.5M | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
总债务DLORARE
| Q4 25 | $86.7M | — | ||
| Q3 25 | $63.1M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $39.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益DLORARE
| Q4 25 | $569.4M | $-80.0M | ||
| Q3 25 | $504.7M | $9.2M | ||
| Q2 25 | — | $151.3M | ||
| Q1 25 | — | $144.2M | ||
| Q4 24 | $489.0M | $255.0M | ||
| Q3 24 | $457.0M | $346.8M | ||
| Q2 24 | — | $432.4M | ||
| Q1 24 | — | $140.3M |
总资产DLORARE
| Q4 25 | $1.5B | $1.5B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $1.3B |
负债/权益比DLORARE
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.08× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $100.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $99.8M | $-100.8M |
| 自由现金流率自由现金流/营收 | 29.5% | -48.6% |
| 资本支出强度资本支出/营收 | 0.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.80× | — |
| 过去12个月自由现金流最近4个季度 | $378.7M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流DLORARE
| Q4 25 | $100.4M | $-99.8M | ||
| Q3 25 | $315.0M | $-91.4M | ||
| Q2 25 | — | $-108.3M | ||
| Q1 25 | — | $-166.5M | ||
| Q4 24 | $-141.1M | $-79.3M | ||
| Q3 24 | $108.3M | $-67.0M | ||
| Q2 24 | — | $-77.0M | ||
| Q1 24 | — | $-190.7M |
自由现金流DLORARE
| Q4 25 | $99.8M | $-100.8M | ||
| Q3 25 | $313.4M | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | $-141.6M | $-79.5M | ||
| Q3 24 | $107.1M | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
自由现金流率DLORARE
| Q4 25 | 29.5% | -48.6% | ||
| Q3 25 | 110.9% | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | -69.2% | -48.3% | ||
| Q3 24 | 57.6% | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
资本支出强度DLORARE
| Q4 25 | 0.2% | 0.5% | ||
| Q3 25 | 0.6% | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.7% | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
现金转化率DLORARE
| Q4 25 | 1.80× | — | ||
| Q3 25 | 2.23× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -4.75× | — | ||
| Q3 24 | 1.19× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DLO
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
